If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Topical Oxybutynin Has Less Cognitive Effects in Older Adults With Overactive Bladder Compared With Oral Dose: Presented at ICS By Sandra Ripley Distelhorst SAN FRANCISCO -- October 3, 2009 -- Topically applied oxybutynin has significantly less negative cognitive effect in older adults with overactive bladder, compared with oral oxybutynin immediate release, researchers reported here at the 39th Annual Meeting of the International Continence Society (ICS). “This study suggests additional safety and tolerability advantages to topical oxybutynin over oral oxybutynin, for both cognitive function and adverse effects” said Gary G. Kay, PhD, Cognitive Research Corporation, who presented the results from a double-blind, placebo-controlled study on October 1. The study used sensitive cognitive and psychomotor testing to compare the effects of oxybutynin transdermal gel (OTG) and oxybutynin immediate-release (OXY-IR) capsules. The study included 152 healthy men and women aged 60 to 79 years of age without dementia. Of these, 49 received OTG, 52 received OXY-IR, and 51 received placebo. Baseline characteristics, including age, were similar between groups. On day 8 patients’ cognitive function was assessed using Name-Face Association test, First-Last Name Association Test, and Misplaced Objects Test. Three patients in the OXY-IR dropped out of the study due to adverse effects and did not complete the cognitive evaluation at day 8. Name-Face Association Test and First-Last Name Association Test showed no significant treatment effect for all 3 groups (P = .273). However, the Misplaced Objects Test showed a significant treatment effect (P = .023), with placebo and OTG scores both improving and OXY-IR scores decreasing (OTG vs placebo [P = .368]; OXY-IR vs placebo [P = .069]). No significant treatment related group differences were demonstrated on measures of psychomotor reaction time. However, analysis of reliable change scores in the Hopkins Verbal Learning Test-Total Free Recall found 10 subjects showed a significant decline on OXY-IR, compared with 6 subjects on placebo and 5 subjects on OTG. The study authors concluded that topical oxybutynin use in healthy elderly adults is comparable with placebo in its lack of effects on sensitive tests of recent memory and other cognitive functions. Funding for this study was provided by Watson Laboratories. [Presentation title. Are the Effects of Oxybutynin on Cognition Dependent Upon the Route of Administration - Topical or Oral? A Double-Blind Placebo Controlled Study Employing Sensitive Cognitive and Psychomotor Testing. Abstract 111]
|
